CYP2C19 and metabolic dysfunction-associated steatotic liver disease: Upon subsequent literature review, we identified a study that demonstrated hepatosteatosis was significantly associated with a lack of clopidogrel anti-platelet effect, further supporting our hypothesis that CYP2C19 downregulation puts NAFLD patients at increased risk for clopidogrel treatment failure62.